Project Grant R01CA285566
Award Date
7/2/24
Completion Date
6/30/29
Dollars Obligated
$577K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This $178,909 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Emory University to advance novel therapies and translational science to address survivorship gaps in pediatric, adolescent, and young adult (AYA) lymphoma. The project aims to accelerate the incorporation of immunotherapy and CD30-targeted cellular therapy into clinical trials for children and AYAs, both for initial therapy and relapsed/refractory...
The National Cancer Institute awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine to conduct research aimed at understanding how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The research will (1) determine how MYCN rewires T cell metabolism to promote immune suppression, and (2) elucidate how MYCN-induced lipogenesis contributes to a suppressive tumor immune microenvironment. This research is vital...
This $709,554 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Emory University to advance understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to: Gain insight into how blocking the SEMA4D protein impacts dendritic cells and macrophages, and increases proximity of B cells to T cells in the tumor microenvironment....
This $635,173 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the mechanisms by which the MYCN oncogene promotes an immunosuppressive tumor microenvironment in high-risk neuroblastoma. The research team, led by investigators at Boston University Medical Campus, will leverage zebrafish models and human patient samples...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research at Boston Children's Hospital to develop a novel precision immunotherapy strategy using genetically engineered tumor-specific B cells. The $249,645 grant, awarded on January 1, 2025, will fund investigations into leveraging homology-driven gene editing to rapidly generate B cells targeting the HER2 tumor antigen. The research aims to evaluate the efficacy and...
The National Cancer Institute (NCI) awarded a $293,369 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Duke University to investigate the mechanisms by which residual tumor cells evade the immune system after treatment with oncogene-targeted therapies. The grant will fund a series of integrative transcriptomics and functional genomics studies to uncover potential mechanisms to target and engineer the immune-mediated clearance of residual tumor cells. The research aims to elucidate...
The National Cancer Institute (NCI) awarded a $664,304 Project Grant (CFDA 93.393 Cancer Cause and Prevention Research) to Emory University to investigate the biological and social determinants of psychosocial outcomes in advanced head and neck cancer patients receiving immunotherapy. The goal is to understand the psychosocial impact of immunotherapy, including factors like inflammation, gut microbiome, and social determinants, and develop targeted interventions to improve quality of life and...
This Project Grant, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $625,994 to Emory University to support research on novel cell therapy approaches for neuroblastoma. The project aims to advance the development of new treatments for this type of pediatric cancer, which is a priority area for military medical research. Emory University, a leading academic research institution, is well-positioned to conduct this work,...
The Department of the Army Medical Command awarded a $541,681 project grant to Dana-Farber Cancer Institute, Inc. to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for battlefield...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $503,194 to Seattle Children's Hospital to assess the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager (MTE) in treating neuroblastoma. The research aims to determine the vulnerability of patient-derived neuroblastomas to the MTE and its efficacy in tumors with heterogeneous ROR1 expression. The innovation lies in co-targeting ROR1 and PD-L1 to address resistance...